Andrew M Davidoff1. 1. Department of Surgery, St Jude Children's Research Hospital, University of Tennessee College of Medicine, Memphis, TN 38105-3678, USA. andrew.davidoff@stjude.org
Abstract
PURPOSE OF REVIEW: Wilms' tumor accounts for nearly 6% of all pediatric cancers and more than 95% of all kidney tumors in children. Fortunately, survival for patients with Wilms' tumor is generally excellent. This review will outline the results of prior clinical trials that have led to this excellent outcome and how information gleaned from these trials has led to the development of the current series of clinical trials for the management of children with Wilms' tumor. RECENT FINDINGS: Tumor stage and histologic subtype have long been recognized as important prognostic factors in Wilms' tumor. More recent evidence suggests that, in certain instances, patient age, tumor size, response to therapy, and genetic abnormalities, specifically the loss of genetic material on chromosomes 1p and 16q, provide additional prognostic information. These factors have, therefore, been incorporated into a new risk stratification system that is currently being used to assign patients with Wilms' tumor to specific protocol-based therapies. SUMMARY: Survival for patients with Wilms' tumor when considered as a whole, once less than 30%, is currently greater than 90%, with this dramatic improvement being due, in part, to the systematic manner in which the approach to therapy has evolved. Further refinement in therapy is being undertaken, with the current trials aiming to maintain the excellent survival for children being treated for Wilms' tumor, while minimizing therapy-related toxicity.
PURPOSE OF REVIEW: Wilms' tumor accounts for nearly 6% of all pediatric cancers and more than 95% of all kidney tumors in children. Fortunately, survival for patients with Wilms' tumor is generally excellent. This review will outline the results of prior clinical trials that have led to this excellent outcome and how information gleaned from these trials has led to the development of the current series of clinical trials for the management of children with Wilms' tumor. RECENT FINDINGS:Tumor stage and histologic subtype have long been recognized as important prognostic factors in Wilms' tumor. More recent evidence suggests that, in certain instances, patient age, tumor size, response to therapy, and genetic abnormalities, specifically the loss of genetic material on chromosomes 1p and 16q, provide additional prognostic information. These factors have, therefore, been incorporated into a new risk stratification system that is currently being used to assign patients with Wilms' tumor to specific protocol-based therapies. SUMMARY: Survival for patients with Wilms' tumor when considered as a whole, once less than 30%, is currently greater than 90%, with this dramatic improvement being due, in part, to the systematic manner in which the approach to therapy has evolved. Further refinement in therapy is being undertaken, with the current trials aiming to maintain the excellent survival for children being treated for Wilms' tumor, while minimizing therapy-related toxicity.
Authors: Robert C Shamberger; Gerald M Haase; Pedram Argani; Elizabeth J Perlman; Cecilia A Cotton; Janice Takashima; Daniel M Green; Michael L Ritchey Journal: J Pediatr Surg Date: 2006-04 Impact factor: 2.545
Authors: D M Green; J B Beckwith; N E Breslow; P Faria; J Moksness; J Z Finklestein; P Grundy; P R Thomas; T Kim; S Shochat Journal: J Clin Oncol Date: 1994-10 Impact factor: 44.544
Authors: Christopher Mitchell; Kathy Pritchard-Jones; Rosemary Shannon; Carolyn Hutton; Suzanne Stevens; David Machin; John Imeson; Anna Kelsey; Gordan M Vujanic; Peter Gornall; Jenny Walker; Roger Taylor; Pat Sartori; Juliet Hale; Gill Levitt; Boo Messahel; Helen Middleton; Richard Grundy; Jon Pritchard Journal: Eur J Cancer Date: 2006-08-10 Impact factor: 9.162
Authors: Jeffrey S Dome; Cecilia A Cotton; Elizabeth J Perlman; Norman E Breslow; John A Kalapurakal; Michael L Ritchey; Paul E Grundy; Marcio Malogolowkin; J Bruce Beckwith; Robert C Shamberger; Gerald M Haase; Max J Coppes; Peter Coccia; Morris Kletzel; Robert M Weetman; Milton Donaldson; Roger M Macklis; Daniel M Green Journal: J Clin Oncol Date: 2006-05-20 Impact factor: 44.544
Authors: G J D'Angio; N Breslow; J B Beckwith; A Evans; H Baum; A deLorimier; D Fernbach; E Hrabovsky; B Jones; P Kelalis Journal: Cancer Date: 1989-07-15 Impact factor: 6.860
Authors: Andrew M Davidoff; Dana W Giel; Deborah P Jones; Jesse J Jenkins; Matthew J Krasin; Fredric A Hoffer; Mark A Williams; Jeffrey S Dome Journal: Cancer Date: 2008-05-01 Impact factor: 6.860
Authors: Jason Axt; Fatmah Abdallah; Meridith Axt; Jessie Githanga; Erik Hansen; Joel Lessan; Ming Li; Joyce Musimbi; Michael Mwachiro; Mark Newton; James Ndung'u; Festis Njuguna; Ancent Nzioka; Oliver Oruko; Kirtika Patel; Robert Tenge; Flora Ukoli; Russel White; James A O'Neill; Harold N Lovvorn Journal: J Pediatr Surg Date: 2013-06 Impact factor: 2.545
Authors: Geetika Khanna; Nancy Rosen; James R Anderson; Peter F Ehrlich; Jeffrey S Dome; Kenneth W Gow; Elizabeth Perlman; Douglas Barnhart; Kathryn Karolczuk; Paul Grundy Journal: Pediatr Blood Cancer Date: 2011-06-14 Impact factor: 3.167
Authors: Andrew J Murphy; Janene Pierce; Christian de Caestecker; Jaime Libes; David Neblett; Mark de Caestecker; Alan O Perantoni; Shunsuke Tanigawa; James R Anderson; Jeffrey S Dome; Amrita Das; Thomas J Carroll; Harold N Lovvorn Journal: Pediatr Blood Cancer Date: 2013-09-20 Impact factor: 3.167
Authors: Andrew J Murphy; Jason R Axt; Christian de Caestecker; Janene Pierce; Hernan Correa; Erin H Seeley; Richard M Caprioli; Mark W Newton; Mark P de Caestecker; Harold N Lovvorn Journal: Int J Cancer Date: 2012-04-04 Impact factor: 7.396
Authors: Jaime M Libes; Erin H Seeley; Ming Li; Jason R Axt; Janene Pierce; Hernan Correa; Mark Newton; Erik Hansen; Audra Judd; Hayes McDonald; Richard M Caprioli; Arlene Naranjo; Vicki Huff; James A O'Neill; Harold N Lovvorn Journal: J Am Coll Surg Date: 2014-01-24 Impact factor: 6.113